Treating advanced radioresistant differentiated thyroid cancer
Mené sur 145 patients atteints d'un carcinome différencié de la thyroïde, métastatique ou localement avancé, cet essai européen de phase II évalue, du point de vue de la survie sans progression, le vandetanib
Despite a decline in overall mortality from cancer in the USA, thyroid cancer incidence has more than doubled in the past decade, with an associated rise in mortality. Thyroid cancer is the fifth most common new cancer diagnosis in women and the eighth most common new cancer diagnosis in the USA overall; it is now more frequently diagnosed than all leukaemias combined, as well as ovarian, uterine, pancreatic, or oesophageal cancers. Equivalent or even more pronounced increases in thyroid cancer incidence have been noted worldwide, mainly because of rises in incidences of papillary thyroid cancer. For example, thyroid cancer is the second most common new cancer diagnosis in women in the Middle East. Most patients with thyroid cancer have an excellent prognosis, with overall annual mortality of about 3% in the USA. Thyroid cancer nevertheless accounts for more deaths in the USA at present than Hodgkin's lymphoma, osteosarcoma, or testicular cancer (by a factor of more than three)—with few treatment options for patients with aggressive disease...
The Lancet Oncology , commentaire en libre accès, 2011